(-)-Blebbistatin: Selective Non-Muscle Myosin II Inhibitor for Cytoskeletal Dynamics Research

Executive Summary: (-)-Blebbistatin (CAS 856925-71-8) is a cell-permeable small molecule that selectively inhibits non-muscle myosin II (NM II) in a reversible manner, with an IC50 of 0.5–5.0 μM under standard in vitro conditions (APExBIO). It binds the myosin-ADP-phosphate complex, suppressing Mg-ATPase activity and actomyosin contractility without significantly affecting myosin isoforms I, V, or X (Lange et al., 2021). The compound is insoluble in water and ethanol but dissolves in DMSO at ≥14.62 mg/mL. Widely adopted in cytoskeletal dynamics, cardiac muscle research, and animal modeling, (-)-Blebbistatin enables precise modulation of cell mechanics and mechanotransduction (see comparison). Storage below -20°C preserves stability for several months.

Biological Rationale

Non-muscle myosin II (NM II) is an actin-dependent motor protein central to cell adhesion, migration, cytokinesis, and tissue morphogenesis (Lange et al., 2021). Dysregulation of NM II activity underlies diverse pathologies, including MYH9-related disease, cancer progression, and cardiac arrhythmias. Controlling NM II function is essential for dissecting cytoskeletal mechanics and related signaling pathways such as caspase and actomyosin contractility. Pharmacological inhibition using selective agents like (-)-Blebbistatin enables reversible, temporally precise perturbation of these processes, facilitating studies of cell structure, mechanotransduction, and disease modeling (further mechanomemory context).

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin acts by binding to the myosin-ADP-phosphate complex in NM II, stabilizing it in a conformation that prevents phosphate release (APExBIO). This suppression inhibits Mg-ATPase activity, blocking actomyosin-driven contractility. The inhibition is reversible upon washout, supporting dynamic experimental designs. The compound exhibits minimal activity on myosin I, V, and X (IC50 >> 100 μM), and displays reduced potency toward smooth muscle myosin II (IC50 ~80 μM), confirming its selectivity profile. (-)-Blebbistatin does not disrupt actin polymerization or other cytoskeletal motor functions, which distinguishes it from less selective small molecules.

Evidence & Benchmarks

• (-)-Blebbistatin inhibits NM II Mg-ATPase activity with an IC50 ranging from 0.5 to 5.0 μM under in vitro conditions (APExBIO).
• In animal models of persistent atrial fibrillation, NM II inhibition alters conduction velocity and cell contractility, supporting direct involvement in cardiac mechanics (Lange et al., 2021).
• Minimal inhibition of myosin I, V, and X (IC50 >> 100 μM) and reduced activity on smooth muscle myosin II (IC50 ~80 μM) confirm selectivity (APExBIO).
• Solubility in DMSO is ≥14.62 mg/mL, supporting preparation of concentrated stock solutions for cell-based assays (APExBIO).
• Use in zebrafish embryo models induces dose-dependent cardia bifida, validating developmental biology applications (see comparison).

Compared to previous coverage of actomyosin contractility pathways, this article provides updated benchmarks on selectivity and solubility relevant for protocol optimization.

Applications, Limits & Misconceptions

(-)-Blebbistatin is widely used in research on cell adhesion, migration, cardiac contractility, and mechanobiology (APExBIO). It is central to studies of cytoskeletal dynamics, MYH9-related disease modeling, and tumor mechanics. Its reversible nature allows for temporal control of myosin II-driven processes in live-cell imaging and tissue engineering. In cardiac studies, (-)-Blebbistatin modulates actin-myosin interaction, affecting contractility and calcium wave propagation (see cardiac research context). The compound is also adopted in animal models (e.g., zebrafish embryos) to study morphogenesis and developmental defects.

Common Pitfalls or Misconceptions

• (-)-Blebbistatin is not effective against myosin isoforms I, V, or X at standard research concentrations (IC50 >> 100 μM).
• It does not directly inhibit actin polymerization or disrupt cytoskeletal architecture independent of myosin II.
• The compound is insoluble in water and ethanol; use of DMSO is required for stock solution preparation.
• Stability is limited in solution at room temperature; solutions should be used promptly and stored below -20°C.
• Photoinstability and potential cytotoxicity may arise under prolonged light exposure or high concentrations; use in low-light conditions is recommended.

Workflow Integration & Parameters

Stock solutions of (-)-Blebbistatin can be prepared in DMSO at concentrations of ≥14.62 mg/mL. Warming and ultrasonic treatment are recommended to enhance solubility. Working solutions are diluted in culture medium immediately before use. Store solid compound at -20°C and aliquoted solutions below -20°C for several months (APExBIO). Rapid degradation may occur at room temperature or upon repeated freeze-thaw cycles. For live-cell work, limit light exposure to minimize photo-degradation. Dosage and exposure time should be optimized based on cell type, with typical working concentrations in the 1–10 μM range. Reversibility supports dynamic experimental workflows, enabling both acute and chronic studies of cytoskeletal function.

Conclusion & Outlook

(-)-Blebbistatin, as supplied by APExBIO (SKU B1387), is a rigorously benchmarked, highly selective tool for dissecting non-muscle myosin II function in cell biology, cardiac physiology, and developmental models. Its solubility, reversible mechanism, and specificity underpin robust, reproducible experiments in mechanobiology and disease modeling. Future developments include combinatorial use with advanced imaging and genetic tools to further unravel cytoskeletal dynamics and their pathophysiological implications.